A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis
ConditionPsoriasis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-70
SponsorInventisBio Co., Ltd
About this trial
A Study looking at the safety and efficacy of D-2570 in Participants with Plaque Psoriasis
Eligibility criteria
Qualifiers
Participants with a diagnosis of plaque psoriasis with no significant flares of disease activity for at least 6 months before signing the informed consent
Participants have moderate to severe plaque psoriasis as defined by a total body surface area (BSA) ≥10%, a Psoriasis Area and Severity Index (PASI) score ≥ 12 and a Physician's Global Assessment (PGA) score ≥ 3.
Within normal ranges of laboratory assessments
Disqualifiers
Any comorbidities or past medical conditions as outlined in the protocol that would interfere with study assessments as deemed by the Investigator
Trial design
Treatments tested in this trial
- D-2570 Tablet
- Placebo Tablets
Treatment groups
75 Participants
are divided into 3 treatment groupsLocations
2Study Center35244, BirminghamAlabama, United States
Study Center91910, Chula VistaCalifornia, United States
Sponsors and collaborators
InventisBio Co., Ltd
Lead sponsor
Source ClinicalTrials.gov